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COMMENTARY
How personalised medicine will transform 
healthcare by 2030: the ICPerMed vision
Astrid M. Vicente1,2*, Wolfgang Ballensiefen3 and Jan‑Ingvar Jönsson4,5
Abstract 
This commentary presents the vision of the International Consortium for Personalised Medicine (ICPerMed) on how 
personalised medicine (PM) will lead to the next generation of healthcare by 2030. This vision focuses on five per‑
spectives: individual and public engagement, involvement of health professionals, implementation within healthcare 
systems, health‑related data, and the development of sustainable economic models that allow improved therapy, 
diagnostic and preventive approaches as new healthcare concepts for the benefit of the public. We further identify 
four pillars representing transversal issues that are crucial for the successful implementation of PM in all perspectives. 
The implementation of PM will result in more efficient and equitable healthcare, access to modern healthcare meth‑
ods, and improved control by individuals of their own health data, as well as economic development in the health 
sector.
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Personalised medicine (PM) represents an exciting 
opportunity to improve the future of individualised 
healthcare for all citizens (citizen herein equivalent to 
individuals in the society, reflecting the inclusive and fair 
nature of PM approaches), holding much promise for dis-
ease treatment and prevention. There are high expecta-
tions for the future, but will PM and its accompanying 
tools and approaches change healthcare and be widely 
implemented for the benefit of society and its citizens by 
2030? Will scientists, innovators, healthcare providers, 
and others be able to provide the most suitable medi-
cine, at the right dose, for the right person, at the right 
time, at a reasonable cost? Will the healthcare sector be 
able to find the incentives and create appropriate finan-
cial models to implement PM in daily clinical practice? 
These are questions that require immediate attention and 
coordinated action to achieve the goal of the comprehen-
sive implementation of PM already by 2030.
The International Consortium for Personalised Medi-
cine (ICPerMed) [1] believes that advancement of the 
biomedical, social, and economic sciences, together with 
technological development, is the driving force for PM. 
Strong investment in research and innovation is there-
fore a prerequisite for its successful implementation. 
Here, we present our vision of how PM will lead to the 
next generation of healthcare by 2030. Through five main 
perspectives, our vision affirms PM as a medical prac-
tice centred on the individual’s characteristics, leading to 
improved effectiveness of diagnostics, treatment and pre-
vention, added economic value, and equitable access for 
all citizens.
ICPerMed envisages healthcare within the five core 
perspectives, further delineated in our white paper [2], to 
be implemented by 2030 as follows:
Perspective 1: Informed, empowered, engaged, and 
responsible citizens
• Health-related data is controlled by the citizen, 
including input, monitoring, and access.
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• Easily accessible, reliable, and understandable sources 
of medical information are available.
Perspective 2: Informed, empowered, engaged, and 
responsible health providers
• The safe, responsible, and optimal use of health infor-
mation and research results required for PM is rou-
tine in clinical settings.
• Clinical decisions requiremultidisciplinary teams, 
integrating novel health-related professions.
• The education of healthcare professionals has 
adopted the interdisciplinary aspects of PM.
• Clinicians and researchers work closely to support 
the rapid development and implementation of PM 
solutions.
Perspective 3: Healthcare systems enable personally 
tailored, optimised health promotion and disease preven-
tion, diagnosis, and treatment for the benefit of patients
• Equitable access to PM services for all citizens is a 
reality.
• PM services are optimised in terms of effectiveness 
and equity.
• The allocation of resources within healthcare systems 
is consistent with societal values.
• Secure health data flow from citizens and healthcare 
systems to regulatory authorities and research is in 
place.
Perspective 4: Available health-related information for 
optimised treatment, care, prevention, and research
• Personal data in electronic health records (EHRs) 
is used by healthcare providers and researchers for 
more efficient PM.
• Harmonised solutions to ensure data privacy, safety, 
and security are applied in health-data management.
• Optimised treatment and prevention based on per-
sonal data benefit citizens, while minimising costs 
and risks.
Perspective 5: Economic value by establishing the next 
generation of medicine
• A reasonable balance between investment, profit, 
and shared benefit for the citizen is a reality for PM.
• Appropriate business concepts and models are in 
place for PM.
• Telemedicine and mobile solutions promote PM and 
are of economic value.
• New jobs in healthcare systems are created.
The ICPerMed vision for 2030 is aligned with the 
goals of the United Nations 2030 Agenda for Sustainable 
Development, which sets out a vision for good health and 
well-being, promoting healthy lifestyles, preventive meas-
ures, and modern, efficient healthcare for everyone. To 
support these goals and sustain the five perspectives of 
the ICPerMed vision, four pillars representing transver-
sal issues are crucial for the successful implementation of 
PM (Fig. 1):
• Data and technology.
By 2030, digital technology is a ubiquitous enabler of 
all aspects of society, including the health and well-being 
of citizens. Attitudes towards digital technology and data 
sharing have changed, driven by a new generation for 
whom digital technology and social networks are fully 
integrated in daily life. These citizens are more empow-
ered to control their health data than those of previous 
generations, and thus more engaged in healthcare deci-
sions and data sharing for research. Adequate regula-
tory frameworks and data management protocols for the 
protection of personal rights are compliant with interna-
tional state-of-the-art standards addressing data security, 
accessibility, storage, and curation.
Comprehensive personal health data is, in 2030, 
available through EHRs. The widespread use of wear-
able devices and apps allows continuous and real-time 
tracking of health parameters and behaviours, which 
is complemented by biomarker technology. The global 
efforts to understand genomic variation in millions of 
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Fig. 1 The ICPerMed vision for 2030–a framework of five perspectives 
addressing the role of the individual, the role of health professionals, 
the implementation of PM in health systems, the use of personal 
health‑related information, and the economic value of PM 
approaches, sustained by four critical pillars representing transversal 
issues crucial for the implementation of PM
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individuals allow the definition of individual genomic 
risk profiles associated with common diseases, placing 
greater emphasis on prevention. Other levels of biolog-
ical information, including epigenomics, proteomics, 
and metabolomics complement genomic-risk estimates 
and provide monitoring tools for individuals at risk 
for disease. Data generation is continuously evolving, 
requiring innovative and flexible information and com-
munication technology (ICT) solutions to address the 
needs of PM models for data storage, management, 
access, safety, and sharing. Interoperability and har-
monisation concepts are embedded in healthcare and 
research systems through more homogeneous data col-
lection tools. Significant investments in artificial intel-
ligence methods by 2030 lead to novel and efficient 
integration and interpretation of multilevel data from a 
wide range of sources. Finally, creative and trustworthy 
ICT solutions are available to support clinical decisions 
by healthcare providers at the point-of-care.
• Inter-sectoral synergies.
In the ICPerMed vision for 2030, strong synergies 
between healthcare and research are crucial for the 
application of PM. Large volumes of routine health-
care data provide a rich source of material for research, 
allowing patient stratification and the definition of 
individual profiles and supporting adapted clinical 
trials. A close alignment between healthcare provid-
ers, researchers, and patients, together with improved 
flexibility of healthcare systems, enables end user-
driven biomedical and clinical research and supports 
the rapid assimilation of research results by the clinic. 
The healthcare systems of 2030 support research to 
strengthen the evidence base of novel PM strategies, 
effectiveness, and value.
Other parameters influencing health outcomes, includ-
ing lifestyle and behaviour, socio-economic status, 
employment, and environmental exposure are integrated 
with personal health and biomarker data. Acknowledging 
the impact of policies from other sectors enables valuable 
inter-sectoral synergies, particularly for health promo-
tion and disease prevention.
In 2030, synergies with the private sector are driven 
by the need for rapid technological progress, along with 
novel business opportunities and models. PM drives 
innovation, particularly in areas such as digital technol-
ogy, biomarker detection, and the development of molec-
ular-targeted drugs. Through close cooperation with the 
pharma industry, data from clinical trials is available to 
the medical community, improving patient access to 
innovative medicines. Health technology assessment 
clarifies the true value of technologies, incentivizing PM.
• Healthcare system reforms.
By 2030, the primary focus of healthcare has shifted 
from treatment to risk definition, patient stratification, 
and personalised health promotion and disease preven-
tion strategies of particular value for ageing societies. 
Optimisation of healthcare systems until 2030 reflects 
this change. Economic sustainability and societal ben-
efits of PM are clear and integrate a societal perspec-
tive. Economic analysis is at a systemic level, integrating 
unemployment, social-care systems, new risk-sharing 
methods, and the entire life cycle of PM approaches. This 
broader societal perspective is underpinned by shared 
ethical values and equity of access for all, including mar-
ginalised sectors and under-served populations. In 2030, 
adequate reimbursement models are in place to support 
this more equitable approach, and consider the long-
term value of innovative technology-based approaches.
Significant investments in technological infrastructure 
and digital platforms until 2030 maximize the enormous 
economic value of public ownership of data and create 
the need for new skills and novel professional profiles. 
Health professionals trained in digital technologies, bio-
marker examination, and data analysis are members of 
multidisciplinary teams that make shared clinical deci-
sions. Healthcare systems use flexible working models 
to accommodate individual needs and incorporate the 
rapid turnover of technological and scientific innova-
tions streaming from research, and bidirectional data 
accessibility is facilitated by networking and data-sharing 
platforms.
• Education and literacy.
Major changes in medical and other healthcare pro-
vider curricula (e.g. pharmacists, nurses, and therapists) 
result in a new generation of informed, empowered, 
engaged, and responsible healthcare providers by 2030. 
There is a strong focus on digital literacy and the skills 
needed to interpret biomarker information. The value of 
multidisciplinarity in clinical and healthcare decisions 
is routinely used in practice. Given the fast turnover of 
technologies and their potential impact on healthcare, 
lifelong education and training is essential for healthcare 
providers. Conversely, professionals with non-clinical 
backgrounds have a better understanding of healthcare 
and clinical issues, facilitating interactions amongst clini-
cal teams.
For the citizen, health data education and literacy 
in PM, including ethical, regulatory, and data-control 
issues, is provided through schools and specific liter-
acy programs. Improved PM literacy is complemented 
by interfaces capable of providing required rigorous 
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information on demand while preserving the patient-cli-
nician interaction.
In 2030, healthcare managers and policy makers have 
ample evidence of the benefits of PM to citizens and 
healthcare systems. This enables the establishment of 
political frameworks to tackle effectiveness, efficiency, 
equity, and ethical issues underlying the development 
and implementation of PM approaches.
Conclusions
PM is not so much a paradigm change as the evolution 
of medicine in a biotechnology and data-rich era. This 
development requires extensive adjustments in the way 
healthcare is provided, including new skills for healthcare 
professionals and novel tools for delivery. The ICPerMed 
vision reflects such an evolution. It was supported by 
consulting European and international experts, covering 
key sectors, who provided feedback on the opportunities 
and challenges of PM and highlighted specific concerns 
and possible solutions [2].
ICPerMed supports coordinated research directed 
towards the progressive implementation of PM and 
has previously developed an Action Plan [3], defining 
research activities to stimulate the adoption of PM in 
healthcare. Leveraging the Action Plan, ICPerMed mem-
bers have been successful in establishing PM research 
and healthcare programs and actions in their own coun-
tries and regions [4]. The European Commission already 
supports many initiatives consistent with the presented 
vision and, together with ICPerMed, is committed to 
expanding its efforts globally. The core perspectives of 
the ICPerMed vision and transversal issues presented 
herein can further orient policy makers and guide the 
healthcare community in their planning of future pro-
grams and activities for PM implementation. ICPerMed 
will continue to act as a communication platform for 
existing and future initiatives and organisations related to 
PM, paving the way towards this vision of PM in 2030.
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